Tyme Technologies, Inc. (TYME) Income Statement Analysis

See more : Materials Analysis Technology Inc. (3587.TWO) Income Statement Analysis – Financial Results

Complete financial analysis of Tyme Technologies, Inc. (TYME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyme Technologies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Hanwha Solutions Corporation (009835.KS) Income Statement Analysis – Financial Results
Koninklijke Philips N.V. (PHI1.DE) Income Statement Analysis – Financial Results
Kyodo Paper Holdings (9849.T) Income Statement Analysis – Financial Results
Geomega Resources Inc. (GOMRF) Income Statement Analysis – Financial Results
Cerebra Integrated Technologies Limited (CEREBRAINT.BO) Income Statement Analysis – Financial Results

Tyme Technologies, Inc. (TYME)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.tymeinc.com

About Tyme Technologies, Inc.

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	13.44M	17.03M	12.96M	14.72M	8.84M	6.11M	3.82M	0.00	0.00	0.00	0.00
General & Administrative	9.63M	10.19M	12.80M	14.59M	10.52M	9.10M	4.78M	53.91K	56.59K	27.43K	2.10K
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	9.63M	10.19M	12.80M	14.59M	10.52M	9.10M	4.78M	53.91K	56.59K	27.43K	2.10K
Other Expenses	2.44M	0.00	0.00	2.47M	0.00	0.00	0.00	0.00	0.00	0.00	-4.20K
Operating Expenses	23.08M	27.22M	25.76M	29.31M	19.36M	15.21M	8.60M	53.91K	56.59K	27.43K	-2.10K
Cost & Expenses	23.08M	27.22M	25.76M	29.31M	19.36M	15.21M	8.60M	53.91K	56.59K	27.43K	2.10K
Interest Income	0.00	22.08K	229.46K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	70.24K	97.13K	114.24K	0.00	0.00	0.00	3.50M	76.56K	0.00	0.00	0.00
Depreciation & Amortization	1.96M	5.18K	5.18K	8.42K	4.30K	4.28K	4.29K	76.56K	0.00	0.00	0.00
EBITDA	-23.56M	-27.22M	-25.76M	-31.78M	-19.36B	-15.21B	-8.60M	22.65K	-56.59K	-27.43K	-2.10K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-25.51M	-27.22M	-25.76M	-31.78M	-19.36M	-15.21M	-8.60M	-53.91K	-56.59K	-27.43K	-2.10K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	1.89M	-1.76M	3.76M	-1.21M	19.34B	15.19B	-3.13M	0.00	0.00	0.00	0.00
Income Before Tax	-23.63M	-28.98M	-22.00M	-32.98M	-18.97M	-15.21M	-11.73M	-53.91K	-56.59K	-27.43K	-2.10K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-1.96M	-1.66M	3.87M	-1.21M	390.39K	0.00	376.26K	0.00	0.00	0.00	0.00
Net Income	-21.67M	-28.98M	-22.00M	-32.98M	-18.97M	-15.21M	-11.73M	-53.91K	-56.59K	-27.43K	-2.10K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.13	-0.22	-0.19	-0.32	-0.21	-0.18	-0.15	0.00	0.00	0.00	0.00
EPS Diluted	-0.13	-0.22	-0.19	-0.32	-0.21	-0.18	-0.15	0.00	0.00	0.00	0.00
Weighted Avg Shares Out	172.21M	134.25M	114.53M	102.35M	90.57M	84.45M	77.85M	52.00M	12.00M	47.60M	39.00M
Weighted Avg Shares Out (Dil)	172.21M	134.25M	114.53M	102.35M	90.57M	84.45M	77.85M	52.00M	12.00M	47.60M	39.00M

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tyme Technologies, Inc. Merger

July 6, 2022newsfilecorp.com

Wilmington, Delaware--(Newsfile Corp. - July 6, 2022) - Rigrodsky Law, P.A. is investigating Tyme Technologies, Inc. ("Tyme") (NASDAQ: TYME) regarding possible breaches of fiduciary duties and other violations of law related to Tyme's agreement to be acquired by Syros Pharmaceuticals,...

SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.

July 5, 2022prnewswire.com

NEW YORK , July 5, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS) in connection with the proposed...

Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving

July 5, 2022pennystocks.com

Penny stocks to watch with news The post Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

TYME Technologies Shares Surge On Merger Agreement With Syros Pharma

July 5, 2022benzinga.com

Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expenses currently estimated to be approximately $60 million. Syros expects to issue.

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

July 5, 2022businesswire.com

CAMBRIDGE, Mass. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to...

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

May 26, 2022seekingalpha.com

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives.

Tyme Technologies shares jump premarket on news board to explore strategic options

March 29, 2022marketwatch.com

Tyme Technologies Inc. TYME, -5.56% , a biotech developing cancer metabolism-based treatments, said Tuesday its board has decided to explore its strategic options and has hired Moelis & Co. as a financial adviser and Faegre Drinker Biddle & Reath LLP...

Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript

February 11, 2022seekingalpha.com

Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript

TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET

January 27, 2022businesswire.com

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30...